Market Closed -
Nasdaq
16:00:00 2024-04-26 EDT
|
5-day change
|
1st Jan Change
|
3.1
USD
|
+3.68%
|
|
-4.02%
|
-3.73%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
198.4
|
146.5
|
218.6
|
131.1
|
227.6
|
219.5
|
-
|
-
|
Enterprise Value (EV)
1 |
198.4
|
146.5
|
218.6
|
131.1
|
227.6
|
219.5
|
219.5
|
219.5
|
P/E ratio
|
-2.69
x
|
-1.66
x
|
1.82
x
|
-2.42
x
|
-4.35
x
|
-4.45
x
|
-13.1
x
|
-5.67
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
11.6
x
|
1.05
x
|
87.2
x
|
581
x
|
17.8
x
|
4.52
x
|
6.89
x
|
EV / Revenue
|
-
|
11.6
x
|
1.05
x
|
87.2
x
|
581
x
|
17.8
x
|
4.52
x
|
6.89
x
|
EV / EBITDA
|
-
|
-
|
1.76
x
|
-2.38
x
|
-3.95
x
|
-4.27
x
|
-281
x
|
-
|
EV / FCF
|
-3,879,703
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
47,816
|
63,435
|
68,092
|
70,467
|
70,681
|
70,811
|
-
|
-
|
Reference price
2 |
4.150
|
2.310
|
3.210
|
1.860
|
3.220
|
3.100
|
3.100
|
3.100
|
Announcement Date
|
20-03-11
|
21-03-15
|
22-03-15
|
23-03-13
|
24-03-08
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
12.62
|
208.4
|
1.503
|
0.3917
|
12.32
|
48.56
|
31.87
|
EBITDA
1 |
-
|
-
|
124.4
|
-55.04
|
-57.68
|
-51.39
|
-0.7813
|
-
|
EBIT
1 |
-61.41
|
-81.43
|
149.2
|
-55.55
|
-59.28
|
-55.69
|
-23.41
|
-49.03
|
Operating Margin
|
-
|
-645.4%
|
71.58%
|
-3,696.43%
|
-15,134.4%
|
-452.17%
|
-48.2%
|
-153.83%
|
Earnings before Tax (EBT)
1 |
-60.46
|
-81.04
|
124.2
|
-54.17
|
-52.34
|
-51.11
|
-19.9
|
-45.89
|
Net income
1 |
-60.46
|
-81.04
|
122.8
|
-54.17
|
-52.34
|
-51.11
|
-19.9
|
-45.89
|
Net margin
|
-
|
-642.26%
|
58.95%
|
-3,604.66%
|
-13,362%
|
-414.98%
|
-40.97%
|
-143.99%
|
EPS
2 |
-1.540
|
-1.390
|
1.760
|
-0.7700
|
-0.7400
|
-0.6971
|
-0.2358
|
-0.5467
|
Free Cash Flow
|
-51.15
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-11
|
21-03-15
|
22-03-15
|
23-03-13
|
24-03-08
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
1.445
|
-
|
0.0111
|
0.0463
|
0.0662
|
0.075
|
0.109
|
0.1416
|
0.0445
|
0.0487
|
0.0528
|
17.07
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-17.79
|
-12.41
|
-12.69
|
-12.99
|
-
|
-
|
EBIT
1 |
-11.68
|
-11.65
|
-14.29
|
-14.3
|
-12.8
|
-12.17
|
-14.89
|
-14.17
|
-12.03
|
-18.19
|
-16.99
|
-17.38
|
-18.15
|
-1.339
|
-17.56
|
Operating Margin
|
-
|
-
|
-988.59%
|
-
|
-115,350.09%
|
-26,302.29%
|
-22,509.52%
|
-18,895.97%
|
-11,038.66%
|
-12,848.51%
|
-38,175.73%
|
-35,707.01%
|
-34,361.54%
|
-7.84%
|
-
|
Earnings before Tax (EBT)
1 |
-11.68
|
-26.35
|
-16.06
|
-14.59
|
-11.97
|
-11.5
|
-13.36
|
-12.41
|
-11.25
|
-15.32
|
-15.39
|
-15.83
|
-16.6
|
0.1696
|
-16.23
|
Net income
1 |
-11.38
|
-26
|
-16.11
|
-14.59
|
-11.97
|
-11.5
|
-13.36
|
-12.41
|
-11.25
|
-15.32
|
-15.52
|
-15.97
|
-16.7
|
-2.817
|
-16.23
|
Net margin
|
-
|
-
|
-1,114.46%
|
-
|
-107,817.75%
|
-24,858.64%
|
-20,187.74%
|
-16,544.44%
|
-10,326.14%
|
-10,823.71%
|
-34,885.39%
|
-32,815.22%
|
-31,612.72%
|
-16.5%
|
-
|
EPS
2 |
-0.1700
|
-0.3800
|
-0.2300
|
-0.2100
|
-0.1700
|
-0.1600
|
-0.1900
|
-0.1800
|
-0.1600
|
-0.2200
|
-0.2138
|
-0.2172
|
-0.2192
|
-0.0300
|
-0.2000
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-10
|
22-03-15
|
22-05-10
|
22-08-09
|
22-11-08
|
23-03-13
|
23-05-05
|
23-08-04
|
23-11-03
|
24-03-08
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-51.1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
110%
|
-34.7%
|
-47.6%
|
-52.4%
|
-1.3%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.06
|
-
|
-
|
-
|
0.14
|
1
|
1
|
1
|
Capex / Sales
|
-
|
-
|
-
|
-
|
35.09%
|
8.12%
|
2.06%
|
3.14%
|
Announcement Date
|
20-03-11
|
21-03-15
|
22-03-15
|
23-03-13
|
24-03-08
|
-
|
-
|
-
|
Average target price
7.167
USD Spread / Average Target +131.18% Consensus |
1st Jan change
|
Capi.
|
---|
| -3.73% | 220M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|